Immunovaccine has signed a collaborative research agreement with OncoTherapy Science to explore the efficacy of their novel peptide cancer antigen in Immunovaccine's DepoVax vaccine delivery technology and enhancement platform.
Immunovaccine claims that its DepoVax platform is a lipid depot-based vaccine delivery and enhancement technology.
Immunovaccine is currently testing the safety and tolerability of DepoVax in a Phase I clinical trial with DPX-0907, a peptide-based therapeutic cancer vaccine targeting patients with breast, ovarian and prostate cancer.
Immunovaccine R&D vice president Marc Mansour said that they are pleased to be collaborating with OncoTherapy Science and evaluating how their DepoVax technology may enhance the potential of these select peptide antigens to create a highly potent, highly specific vaccine candidate.